Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs

Tan, Emily L.C.; Ooi, Eng Eong; Lin, Chin-Yo; Tan, Hwee Cheng; Ling, Ai Ee; Lim, Bing; Stanton, Lawrence W.

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs

Published Date:

Apr 2004

Source:

Emerg Infect Dis. 10(4):581-586.

[PDF-131.59 KB]

Details:

Alternative Title:

Emerg Infect Dis

Personal Author:

Tan, Emily L.C. ; Ooi, Eng Eong ; Lin, Chin-Yo ; Tan, Hwee Cheng ; Ling, Ai Ee ; ... More ▼

Description:

Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti-SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, b-1b, a-n1, a-n3, and human leukocyte interferon a. These findings support clinical testing of approved interferons for the treatment of SARS.

Subject:

[+]

Document Type:

Journal Article

Collection(s):

Emerging Infectious Diseases

Main Document Checksum:

[+]

Supporting Files:

	03-0458-F1.gif	image/gif
	03-0458-F1.jpg	image/jpeg
	03-0458-F2.gif	image/gif
	03-0458-F2.jpg	image/jpeg
	03-0458.nxml	text/plain
	license.txt	text/plain

No Related Documents.

You May Also Like:

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Personal Author:

Vincent, Martin J; Bergeron, Eric; Benjannet, Suzanne; Erickson, Bobbie R; Rollin, Pierre E; Ksiazek, Thomas G; Seidah, Nabil G; Nichol, Stuart T;

Published Date:

Aug 22 2005

Source:

Virol J. 2005; 2:69.

Description:

BackgroundSevere acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.ResultsWe report, however, that chloroquine has strong antiviral effe...

File Type:

[PDF - 847.81 KB]
Interferon-β 1a and SARS Coronavirus Replication

Personal Author:

Hensley, Lisa E.; Fritz, Elizabeth A.; Jahrling, Peter B.; Karp, Christopher; Huggins, John W.; Geisbert, Thomas W.;

Published Date:

Feb 2004

Source:

Emerg Infect Dis. 10(2):317-319.

Description:

A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effec...

File Type:

[PDF - 1.64 MB]
SARS: Systematic Review of Treatment Effects

Personal Author:

Stockman, Lauren J; Bellamy, Richard; Garner, Paul;

Published Date:

Sep 2006

Source:

PLoS Med. 2006; 3(9).

Description:

BackgroundThe SARS outbreak of 2002–2003 presented clinicians with a new, life-threatening disease for which they had no experience in treating and no research on the effectiveness of treatment options. The World Health Organization (WHO) expert pa...

File Type:

[PDF - 180.72 KB]
Meeting report: 32nd International Conference on Antiviral Research

Personal Author:

Tramontano, Enzo; Tarbet, Bart; Spengler, Jessica R.; Seley-Radtke, Katherine; Meier, Chris; Jordan, Robert; Janeba, Zlatko; Gowen, Brian; Gentry, Brian; Esté, José A.; Bray, Mike; Andrei, Graciela; Schang, Luis M.;

Corporate Authors:

International Society for Antiviral Research

Published Date:

July 11 2019

Source:

Antiviral Res. 2019; 169:104550

Description:

The 32nd International Conference on Antiviral Research (ICAR), sponsored by the International Society for Antiviral Research (ISAR), was held in Baltimore, Maryland, USA, on May 12-15, 2019. This report gives an overview of the conference on behalf ...

File Type:

[PDF - 1.60 MB]
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

Personal Author:

Sheahan, Timothy P.; Sims, Amy C.; Zhou, Shuntai; Graham, Rachel L.; Pruijssers, Andrea J.; Agostini, Maria L.; Leist, Sarah R.; Schäfer, Alexandra; Dinnon, Kenneth H.; Stevens, Laura J.; Chappell, James D.; Lu, Xiaotao; Hughes, Tia M.; George, Amelia S.; Hill, Collin S.; Montgomery, Stephanie A.; Brown, Ariane J.; Bluemling, Gregory R.; Natchus, Michael G.; Saindane, Manohar; Kolykhalov, Alexander A.; Painter, George; Harcourt, Jennifer; Tamin, Azaibi; Thornburg, Natalie J.; Swanstrom, Ronald; Denison, Mark R.; Baric, Ralph S.;

Published Date:

April 06 2020

Source:

Sci Transl Med. 2020; 12(541)

Description:

Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Here, we show that the ribonucleoside analog β-d-N|-hydroxycyti...

File Type:

[PDF - 511.02 KB]